<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03028012</url>
  </required_header>
  <id_info>
    <org_study_id>98370</org_study_id>
    <nct_id>NCT03028012</nct_id>
  </id_info>
  <brief_title>TPI Medication Comparison - Ketorolac, Lidocaine, or Dexamethasone</brief_title>
  <official_title>Double-blind, Prospective Comparison of Medications Used in Trigger Point Injections - Ketorolac, Lidocaine, or Dexamethasone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis

      The main hypothesis of this study is that anti-inflammatory medications (ketorolac or
      dexamethasone) will provide longer-lasting and greater pain relief than just lidocaine in
      trigger point injections where a local twitch response is evoked at the time of the
      injection.

      Purpose/Specific Aims

      The primary objective of this study is to compare the efficacy of three substances used in
      TPIs with a LTR identified at the time of the injection: a CS (dexamethasone), a NSAID
      (ketorolac), or only a local anesthetic (lidocaine).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background

      Trigger point injections (TPIs) are a commonly-performed procedures by physicians for the
      treatment of myofascial pain, specifically targeting myofascial trigger points (MTrPs).
      Commonly injected substances include local anesthetic, botulinum toxin, or corticosteroid
      (CS), though non-steroidal anti-inflammatory drugs (NSAIDs) and other substances have been
      reported. A Cochrane review found that intramuscular injection of local anesthetic
      demonstrated moderate evidence of benefit for mechanical neck disorders; no other treatment
      demonstrated greater benefit.

      Great variation is seen in how TPIs are performed, however. The standard method was described
      by Simons and Travell, and is often cited. Hong et al. demonstrated that, similar to the
      technique described by Simons and Travell, obtaining a local twitch response (LTR) was the
      most important factor in producing pain relief. Further research by Shah et al., which
      demonstrated an inflammatory component to MTrPs, also showed a decrease in inflammatory
      cytokines following trigger point injections that obtained a LTR. Despite these findings,
      most studies do not use the LTR method in their TPI techniques.

      Prior studies demonstrated that most patients obtain significant relief from TPI, but did not
      identify differences between injection of CS or other substances. However, none of these
      studies identified LTRs in their injection techniques.

      As can be learned from a review of the published literature on muscular trigger points, the
      cause of this condition is unknown, and no single treatment approach has been established as
      a clearly accepted gold standard treatment. There is evidence, however, that there is an
      inflammatory component associated with trigger points and that obtaining a local twitch
      response is associated with a decrease in local inflammation at the site of a trigger point.
      The combination of injecting an anti-inflammatory medication and obtaining a local twitch
      response has never been studied. The purpose of this study is to examine the comparative
      effectiveness of injectable substances on patient outcome after a TPI with LTR identified,
      namely a CS (dexamethasone), a NSAID (ketorolac), or only a local anesthetic (lidocaine).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2, 2017</start_date>
  <completion_date type="Anticipated">March 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 20, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Responder (&gt;50% NRS relief)</measure>
    <time_frame>3 months</time_frame>
    <description>Participant will complete questionnaire using pre and post-injection numeric rating scale (NRS) from 0-10 with regards to the trigger point(s).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NRS improvement</measure>
    <time_frame>3 months</time_frame>
    <description>Measured on NRS from 0-10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief pain inventory (BPI) improvement</measure>
    <time_frame>3 months</time_frame>
    <description>Participant will self-report their brief pain inventory at each of the four subsequent injections.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Myofascial Pain</condition>
  <arm_group>
    <arm_group_label>Ketorolac</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants may be randomized to receive Ketorolac for their TPI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lidocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants may be randomized to receive Lidocaine for their TPI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants may be randomized to receive Dexamethasone for their TPI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <description>Participants may be randomized to receive Ketorolac for their TPI. This randomized study will compare the efficacy of the three substances used in TPIs.</description>
    <arm_group_label>Ketorolac</arm_group_label>
    <other_name>Toradol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>Participants may be randomized to receive Lidocaine for their TPI. This randomized study will compare the efficacy of the three substances used in TPIs.</description>
    <arm_group_label>Lidocaine</arm_group_label>
    <other_name>Xylocaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Participants may be randomized to receive Dexamethasone for their TPI. This randomized study will compare the efficacy of the three substances used in TPIs.</description>
    <arm_group_label>Dexamethasone</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men or women age 18 or over

          2. At least one active trigger point

        Exclusion Criteria:

          1. Allergy or contraindication to any NSAID, CS, or local anesthetic

          2. Receiving anticoagulant medication

          3. History of bleeding disorder

          4. Pregnant or breast feeding women

          5. Gastrointestinal ulceration

          6. Pre-existing renal disease

          7. Pre-existing congestive heart failure

          8. Diabetes mellitus

          9. Prior myocardial infarction or stroke

         10. Fibromyalgia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan Cushman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthew Brobeck, BS</last_name>
    <phone>801-581-5328</phone>
    <email>matthew.brobeck@hsc.utah.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dan Cushman, MD</last_name>
    <phone>801-587-5458</phone>
    <email>dan.cushman@hsc.utah.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Utah Orthopaedic Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Brobeck</last_name>
      <phone>801-581-5328</phone>
      <email>matthew.brobeck@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Stuart Willick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Cushman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hong CZ. Lidocaine injection versus dry needling to myofascial trigger point. The importance of the local twitch response. Am J Phys Med Rehabil. 1994 Jul-Aug;73(4):256-63.</citation>
    <PMID>8043247</PMID>
  </reference>
  <reference>
    <citation>Krishnan SK, Benzon HT, Siddiqui T, Canlas B. Pain on intramuscular injection of bupivacaine, ropivacaine, with and without dexamethasone. Reg Anesth Pain Med. 2000 Nov-Dec;25(6):615-9.</citation>
    <PMID>11097670</PMID>
  </reference>
  <reference>
    <citation>Garvey TA, Marks MR, Wiesel SW. A prospective, randomized, double-blind evaluation of trigger-point injection therapy for low-back pain. Spine (Phila Pa 1976). 1989 Sep;14(9):962-4.</citation>
    <PMID>2528826</PMID>
  </reference>
  <reference>
    <citation>Frost FA, Jessen B, Siggaard-Andersen J. A control, double-blind comparison of mepivacaine injection versus saline injection for myofascial pain. Lancet. 1980 Mar 8;1(8167):499-500.</citation>
    <PMID>6102230</PMID>
  </reference>
  <reference>
    <citation>McMillan AS, Nolan A, Kelly PJ. The efficacy of dry needling and procaine in the treatment of myofascial pain in the jaw muscles. J Orofac Pain. 1997 Fall;11(4):307-14.</citation>
    <PMID>9656906</PMID>
  </reference>
  <reference>
    <citation>Hameroff SR, Crago BR, Blitt CD, Womble J, Kanel J. Comparison of bupivacaine, etidocaine, and saline for trigger-point therapy. Anesth Analg. 1981 Oct;60(10):752-5.</citation>
    <PMID>7027827</PMID>
  </reference>
  <reference>
    <citation>Ay S, Evcik D, Tur BS. Comparison of injection methods in myofascial pain syndrome: a randomized controlled trial. Clin Rheumatol. 2010 Jan;29(1):19-23. doi: 10.1007/s10067-009-1307-8. Epub 2009 Oct 20.</citation>
    <PMID>19838864</PMID>
  </reference>
  <reference>
    <citation>Ga H, Koh HJ, Choi JH, Kim CH. Intramuscular and nerve root stimulation vs lidocaine injection to trigger points in myofascial pain syndrome. J Rehabil Med. 2007 May;39(5):374-8.</citation>
    <PMID>17549328</PMID>
  </reference>
  <reference>
    <citation>Misirlioglu TO, Akgun K, Palamar D, Erden MG, Erbilir T. Piriformis syndrome: comparison of the effectiveness of local anesthetic and corticosteroid injections: a double-blinded, randomized controlled study. Pain Physician. 2015 Mar-Apr;18(2):163-71.</citation>
    <PMID>25794202</PMID>
  </reference>
  <reference>
    <citation>Karadaş Ö, Gül HL, Inan LE. Lidocaine injection of pericranial myofascial trigger points in the treatment of frequent episodic tension-type headache. J Headache Pain. 2013 May 22;14:44. doi: 10.1186/1129-2377-14-44.</citation>
    <PMID>23698019</PMID>
  </reference>
  <reference>
    <citation>Kamanli A, Kaya A, Ardicoglu O, Ozgocmen S, Zengin FO, Bayik Y. Comparison of lidocaine injection, botulinum toxin injection, and dry needling to trigger points in myofascial pain syndrome. Rheumatol Int. 2005 Oct;25(8):604-11. Epub 2004 Sep 15.</citation>
    <PMID>15372199</PMID>
  </reference>
  <reference>
    <citation>Wheeler AH, Goolkasian P, Gretz SS. A randomized, double-blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome. Spine (Phila Pa 1976). 1998 Aug 1;23(15):1662-6; discussion 1667.</citation>
    <PMID>9704373</PMID>
  </reference>
  <reference>
    <citation>Cheshire WP, Abashian SW, Mann JD. Botulinum toxin in the treatment of myofascial pain syndrome. Pain. 1994 Oct;59(1):65-9.</citation>
    <PMID>7854804</PMID>
  </reference>
  <reference>
    <citation>Benecke R, Heinze A, Reichel G, Hefter H, Göbel H; Dysport myofascial pain study group. Botulinum type A toxin complex for the relief of upper back myofascial pain syndrome: how do fixed-location injections compare with trigger point-focused injections? Pain Med. 2011 Nov;12(11):1607-14. doi: 10.1111/j.1526-4637.2011.01163.x. Epub 2011 Jun 21.</citation>
    <PMID>21692970</PMID>
  </reference>
  <reference>
    <citation>Göbel H, Heinze A, Reichel G, Hefter H, Benecke R; Dysport myofascial pain study group. Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomized double-blind placebo-controlled multicentre study. Pain. 2006 Nov;125(1-2):82-8. Epub 2006 Jun 5.</citation>
    <PMID>16750294</PMID>
  </reference>
  <reference>
    <citation>Esenyel M, Caglar N, Aldemir T. Treatment of myofascial pain. Am J Phys Med Rehabil. 2000 Jan-Feb;79(1):48-52.</citation>
    <PMID>10678603</PMID>
  </reference>
  <reference>
    <citation>Tschopp KP, Gysin C. Local injection therapy in 107 patients with myofascial pain syndrome of the head and neck. ORL J Otorhinolaryngol Relat Spec. 1996 Nov-Dec;58(6):306-10.</citation>
    <PMID>8958538</PMID>
  </reference>
  <reference>
    <citation>Cotchett MP, Landorf KB, Munteanu SE. Effectiveness of dry needling and injections of myofascial trigger points associated with plantar heel pain: a systematic review. J Foot Ankle Res. 2010 Sep 1;3:18. doi: 10.1186/1757-1146-3-18.</citation>
    <PMID>20807448</PMID>
  </reference>
  <reference>
    <citation>Desai MJ, Saini V, Saini S. Myofascial pain syndrome: a treatment review. Pain Ther. 2013 Jun;2(1):21-36. doi: 10.1007/s40122-013-0006-y. Epub 2013 Feb 12.</citation>
    <PMID>25135034</PMID>
  </reference>
  <reference>
    <citation>Soares A, Andriolo RB, Atallah AN, da Silva EM. Botulinum toxin for myofascial pain syndromes in adults. Cochrane Database Syst Rev. 2014 Jul 25;(7):CD007533. doi: 10.1002/14651858.CD007533.pub3. Review.</citation>
    <PMID>25062018</PMID>
  </reference>
  <reference>
    <citation>Liu L, Huang QM, Liu QG, Ye G, Bo CZ, Chen MJ, Li P. Effectiveness of dry needling for myofascial trigger points associated with neck and shoulder pain: a systematic review and meta-analysis. Arch Phys Med Rehabil. 2015 May;96(5):944-55. doi: 10.1016/j.apmr.2014.12.015. Epub 2015 Jan 7. Review.</citation>
    <PMID>25576642</PMID>
  </reference>
  <reference>
    <citation>Robbins MS, Kuruvilla D, Blumenfeld A, Charleston L 4th, Sorrell M, Robertson CE, Grosberg BM, Bender SD, Napchan U, Ashkenazi A; Peripheral Nerve Blocks and Other Interventional Procedures Special Interest Section of the American Headache Society. Trigger point injections for headache disorders: expert consensus methodology and narrative review. Headache. 2014 Oct;54(9):1441-59. doi: 10.1111/head.12442. Epub 2014 Aug 28. Review.</citation>
    <PMID>25168295</PMID>
  </reference>
  <reference>
    <citation>Risser A, Donovan D, Heintzman J, Page T. NSAID prescribing precautions. Am Fam Physician. 2009 Dec 15;80(12):1371-8.</citation>
    <PMID>20000300</PMID>
  </reference>
  <reference>
    <citation>Tekin L, Akarsu S, Durmuş O, Cakar E, Dinçer U, Kıralp MZ. The effect of dry needling in the treatment of myofascial pain syndrome: a randomized double-blinded placebo-controlled trial. Clin Rheumatol. 2013 Mar;32(3):309-15. doi: 10.1007/s10067-012-2112-3. Epub 2012 Nov 9.</citation>
    <PMID>23138883</PMID>
  </reference>
  <reference>
    <citation>Kim DH, Yoon DM, Yoon KB. The effects of myofascial trigger point injections on nocturnal calf cramps. J Am Board Fam Med. 2015 Jan-Feb;28(1):21-7. doi: 10.3122/jabfm.2015.01.140151.</citation>
    <PMID>25567819</PMID>
  </reference>
  <reference>
    <citation>Gerber LH, Shah J, Rosenberger W, Armstrong K, Turo D, Otto P, Heimur J, Thaker N, Sikdar S. Dry Needling Alters Trigger Points in the Upper Trapezius Muscle and Reduces Pain in Subjects With Chronic Myofascial Pain. PM R. 2015 Jul;7(7):711-8. doi: 10.1016/j.pmrj.2015.01.020. Epub 2015 Feb 4.</citation>
    <PMID>25661462</PMID>
  </reference>
  <reference>
    <citation>Kietrys DM, Palombaro KM, Mannheimer JS. Dry needling for management of pain in the upper quarter and craniofacial region. Curr Pain Headache Rep. 2014;18(8):437. doi: 10.1007/s11916-014-0437-0. Review.</citation>
    <PMID>24912453</PMID>
  </reference>
  <reference>
    <citation>Xie P, Qin B, Yang F, Yu T, Yu J, Wang J, Zheng H. Lidocaine Injection in the Intramuscular Innervation Zone Can Effectively Treat Chronic Neck Pain Caused by MTrPs in the Trapezius Muscle. Pain Physician. 2015 Sep-Oct;18(5):E815-26.</citation>
    <PMID>26431135</PMID>
  </reference>
  <reference>
    <citation>Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG; CONSORT. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Int J Surg. 2012;10(1):28-55. doi: 10.1016/j.ijsu.2011.10.001. Epub 2011 Oct 12. Review.</citation>
    <PMID>22036893</PMID>
  </reference>
  <reference>
    <citation>Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994 Mar;23(2):129-38. Review.</citation>
    <PMID>8080219</PMID>
  </reference>
  <reference>
    <citation>Qerama E, Fuglsang-Frederiksen A, Kasch H, Bach FW, Jensen TS. A double-blind, controlled study of botulinum toxin A in chronic myofascial pain. Neurology. 2006 Jul 25;67(2):241-5.</citation>
    <PMID>16864815</PMID>
  </reference>
  <reference>
    <citation>Ojala T, Arokoski JP, Partanen J. The effect of small doses of botulinum toxin a on neck-shoulder myofascial pain syndrome: a double-blind, randomized, and controlled crossover trial. Clin J Pain. 2006 Jan;22(1):90-6.</citation>
    <PMID>16340597</PMID>
  </reference>
  <reference>
    <citation>De Andrés J, Adsuara VM, Palmisani S, Villanueva V, López-Alarcón MD. A double-blind, controlled, randomized trial to evaluate the efficacy of botulinum toxin for the treatment of lumbar myofascial pain in humans. Reg Anesth Pain Med. 2010 May-Jun;35(3):255-60. doi: 10.1097/AAP.0b013e3181d23241.</citation>
    <PMID>20921836</PMID>
  </reference>
  <reference>
    <citation>Kwanchuay P, Petchnumsin T, Yiemsiri P, Pasuk N, Srikanok W, Hathaiareerug C. Efficacy and Safety of Single Botulinum Toxin Type A (Botox®) Injection for Relief of Upper Trapezius Myofascial Trigger Point: A Randomized, Double-Blind, Placebo-Controlled Study. J Med Assoc Thai. 2015 Dec;98(12):1231-6.</citation>
    <PMID>27004309</PMID>
  </reference>
  <reference>
    <citation>Ashkenazi A, Young WB. The effects of greater occipital nerve block and trigger point injection on brush allodynia and pain in migraine. Headache. 2005 Apr;45(4):350-4.</citation>
    <PMID>15836572</PMID>
  </reference>
  <reference>
    <citation>Frost A. Diclofenac versus lidocaine as injection therapy in myofascial pain. Scand J Rheumatol. 1986;15(2):153-6.</citation>
    <PMID>3749828</PMID>
  </reference>
  <reference>
    <citation>Shirokov VA, Potaturko AV, Zakharov IaIu. [Safety and efficacy of movalis injected into trigger points in lumbago-ischialgia syndrome]. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(9):41-4. Russian.</citation>
    <PMID>18833170</PMID>
  </reference>
  <reference>
    <citation>Sternfeld M, Finkelstein Y, Hai E, Hod I. Tension headache treated by anti-inflammatory drug injected into GB 20 acupuncture point. Am J Chin Med. 1986;14(3-4):171-4.</citation>
    <PMID>3799535</PMID>
  </reference>
  <reference>
    <citation>Choi JW, Lee CJ, Lee SM, Shin BS, Jun B, Sim WS. Effect of Hyaluronidase Addition to Lidocaine for Trigger Point Injection in Myofascial Pain Syndrome. Pain Pract. 2015 Oct 7. doi: 10.1111/papr.12362. [Epub ahead of print]</citation>
    <PMID>26443389</PMID>
  </reference>
  <reference>
    <citation>Yamaguchi A, Ogino Y, Iwakoshi C, Karasawa K, Ohki M. [Trigger point therapy for myofascial pain in cancer patients (second report) analysis results of special use-results surveillance by neovitacain® injection]. Gan To Kagaku Ryoho. 2012 Apr;39(4):605-11. Japanese.</citation>
    <PMID>22504686</PMID>
  </reference>
  <reference>
    <citation>Peloso P, Gross A, Haines T, Trinh K, Goldsmith CH, Burnie S; Cervical Overview Group. Medicinal and injection therapies for mechanical neck disorders. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD000319. Review. Update in: Cochrane Database Syst Rev. 2015;5:CD000319.</citation>
    <PMID>17636629</PMID>
  </reference>
  <reference>
    <citation>Shah JP, Phillips TM, Danoff JV, Gerber LH. An in vivo microanalytical technique for measuring the local biochemical milieu of human skeletal muscle. J Appl Physiol (1985). 2005 Nov;99(5):1977-84. Epub 2005 Jul 21.</citation>
    <PMID>16037403</PMID>
  </reference>
  <reference>
    <citation>Venâncio Rde A, Alencar FG, Zamperini C. Different substances and dry-needling injections in patients with myofascial pain and headaches. Cranio. 2008 Apr;26(2):96-103.</citation>
    <PMID>18468269</PMID>
  </reference>
  <reference>
    <citation>Simons DG, Travell JG, Simons LS. Travell &amp; Simons' Myofascial Pain and Dysfunction: The Trigger Point Manual. Upper half of body. Vol. 1. Vol 1: Wolters Kluwer Health; 1999.</citation>
  </reference>
  <reference>
    <citation>Drewes AM, Andreasen A, Poulsen LH. Injection Therapy for Treatment of Chronic Myofascial Pain. J Musculoskelet Pain. 2010;1(3-4):289-294.</citation>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2017</study_first_submitted>
  <study_first_submitted_qc>January 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2017</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Daniel Cushman</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Trigger Point Injections</keyword>
  <keyword>steroid</keyword>
  <keyword>nsaid</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

